ArticleFuture oncology (London, England)2024

OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.

Sara M Tolaney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.